METHODS FOR SLOWING SENESCENCE AND TREATING AND PREVENTING DISEASES ASSOCIATED WITH SENESCENCE
The present invention relates to a method for slowing, preventing or delaying senescence or treating or preventing a disease associated with senescence by administering a therapeutically effective amount of at least one physiological agent that decreases or regulates the blood level, production, function or activity of LH or FSH, or that decreases or regulates the production or activity of activin, or that increases or regulates the blood level, production, function, or activity of inhibin or follistatin.
1 . A method of treating a disease associated with senescence in a human subject, comprising:
administering to the subject a therapeutically effective amount of an agent that decreases the subject's blood level of FSH and that decreases the subject's blood level of LH; wherein:
the agent is administered to the subject such that a therapeutically effective blood level of the agent is achieved;
the agent comprising one or more of GnRH, leuprolide, triptorelin, buserelin, nafarelin, desorelin, histrelin, or goserelin, or a physiologically acceptable analog, metabolite, precursor or salt thereof, and
the disease selected from the group consisting of: polyps of the colon, colorectal cancer, myeloproliferative diseases, Hodgkin's disease, multiple myeloma, transient myeloproliferative disorder (TMD; also known as transient myeloproliferative syndrome), congenital transient leukemia, congenital leukemoid reaction, transient leukaemoid proliferation, transient abnormal myelopoiesis, acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL; also known as erythro-megakaryoblastic leukaemia), polycythemia, thrombocythemia, myelodysplastic syndromes, myelofibrosis, hypereosinophilic syndrome (HES), hairy-cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, prolymphocytic leukemia, common B lineage acute lymphoblastic leukemia, other leukemias, other myelogenous cancers, osteoarthritis, cataracts, macular degeneration, hearing loss, stroke, peripheral neuropathy, COPD, hypertension, type 2 diabetes, sarcopenia, hypertension, primary pulmonary hypertension, congestive heart failure, left ventricular hypertrophy, cardiac valvular disease, esophagitis, esophageal stricture, gastroparesis, chronic pancreatitis, hypercholesterolemia, hypertriglyceridemia, cirrhosis of the liver, hepatitis, cholelithiasis, cholecystitis, ulcerative colitis, inflammatory bowel disease, Crohn's disease, fibromyalgia, obesity, renal failure, proteinuria, gout, hyperuricemia, membranous nephropathy, polyarteritis nodosa, polymyalgia rheumatica, rheumatoid arthritis, progressive systemic sclerosis, migraine headaches, male pattern baldness, sarcoidosis, Wegener granulomatosis, amyloidosis, dermatomyositis, graft versus host disease, systemic lupus erythematosus, seborrheic dermatitis, psoriasiform eczematous dermatitis, papulosquamous eczematous dermatitis, psoriasis, seborrheic keratosis, anagen effluvium, dysphagia, Barrett esophagus, achalasia, Chagas disease, myasthenia gravis, multiple sclerosis, transverse myelitis, Parkinson's disease, squamous cell carcinoma of the lung, adenocarcinoma of the lung, large cell carcinoma of the lung, small cell carcinoma of the lung, esophageal cancer, gastric cancer, pancreatic cancer, hepatocellular cancer, gallbladder carcinomas, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large cell lymphoma, multiple myeloma, Ewing's sarcoma, chondrosarcomas, osteosarcomas, renal cell carcinoma, bladder carcinoma, squamous cell carcinoma of the head and neck, salivary gland tumors, Sjogren syndrome, mixed connective tissue disease, Whipple disease, Paget's disease of bone, osteomalaci, decreased immune function and decreased muscle mass.
2 . The method of claim 1 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of LH or FSH in the subject to less than approximately 0.7 mIU/mL.
3 . The method of claim 1 , wherein the subject is male.
4 . The method of claim 3 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of LH in the subject to approximately 10 mIU/mL.
5 . The method of claim 3 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of LH or FSH in the subject to less than approximately 0.7 mIU/mL.
6 . The method of claim 3 , wherein the achieved therapeutically effective blood level of the administered agent is approximately 10 nM.
7 . The method of claim 3 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of FSH in the subject to approximately 2.0-22.6 mIU/mL.
8 . The method of claim 3 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of FSH in the subject to approximately 22.6 mIU/mL.
9 . The method of claim 3 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of LH in the subject to approximately 0-10 mIU/mL.
10 . The method of claim 1 , wherein the subject is female.
11 . The method of claim 10 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of LH in the subject to at or near 0.4 mIU/mL in the subject.
12 . The method of claim 10 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of LH or FSH in the subject to less than approximately 0.7 mIU/mL.
13 . The method of claim 10 , wherein the achieved therapeutically effective blood level of the administered agent is approximately 10 nM.
14 . The method of claim 10 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of FSH in the subject to approximately 2.9 mIU/mL.
15 . The method of claim 10 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of FSH in the subject to approximately 2.9-29.5 mIU/mL.
16 . The method of claim 1 wherein the blood level of LH or FSH is decreased using a time-released dose of the agent such that a therapeutically effective blood level of the agent is achieved.
17 . The method of claim 16 , wherein the administering of the therapeutically effective amount of the agent is effective to decrease the blood level of LH in the subject to approximately 0-10 mIU/mL, and wherein the subject is male.
18 . The method of claim 16 , wherein the achieved therapeutically effective blood level of the administered agent is approximately 10 nM.
19 . A method of treating a disease associated with senescence in a human subject, comprising:
administering to the subject a therapeutically effective amount of an agent that decreases the subject's blood level of LH in the subject to at or near 0 mIU/mL in order to treat a disease associated with senescence, the subject being a male over the age of 35 years old,
said agent comprising one or more of the following, or a physiologically acceptable analog, metabolite, precursor or salt thereof: GnRH; leuprolide; triptorelin; buserelin; nafarelin; desorelin; histrelin; or goserelin;
and wherein said disease is selected from the group consisting of: polyps of the colon, colorectal cancer, myeloproliferative diseases, Hodgkin's disease, multiple myeloma, transient myeloproliferative disorder (TMD; also known as transient myeloproliferative syndrome), congenital transient leukemia, congenital leukemoid reaction, transient leukaemoid proliferation, transient abnormal myelopoiesis, acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL; also known as erythro-megakaryoblastic leukaemia), polycythemia, thrombocythemia, myelodysplastic syndromes, myelofibrosis, hypereosinophilic syndrome (HES), hairy-cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, prolymphocytic leukemia, common B lineage acute lymphoblastic leukemia, other leukemias, other myelogenous cancers, osteoarthritis, cataracts, macular degeneration, hearing loss, stroke, peripheral neuropathy, COPD, hypertension, type 2 diabetes, sarcopenia, hypertension, primary pulmonary hypertension, congestive heart failure, left ventricular hypertrophy, cardiac valvular disease, esophagitis, esophageal stricture, gastroparesis, chronic pancreatitis, hypercholesterolemia, hypertriglyceridemia, cirrhosis of the liver, hepatitis, cholelithiasis, cholecystitis, ulcerative colitis, inflammatory bowel disease, Crohn's disease, fibromyalgia, obesity, renal failure, proteinuria, gout, hyperuricemia, membranous nephropathy, polyarteritis nodosa, polymyalgia rheumatica, rheumatoid arthritis, progressive systemic sclerosis, migraine headaches, male pattern baldness, sarcoidosis, Wegener granulomatosis, amyloidosis, dermatomyositis, graft versus host disease, systemic lupus erythematosus, seborrheic dermatitis, psoriasiform eczematous dermatitis, papulosquamous eczematous dermatitis, psoriasis, seborrheic keratosis, anagen effluvium, dysphagia, Barrett esophagus, achalasia, Chagas disease, myasthenia gravis, multiple sclerosis, transverse myelitis, Parkinson's disease, squamous cell carcinoma of the lung, adenocarcinoma of the lung, large cell carcinoma of the lung, small cell carcinoma of the lung, esophageal cancer, gastric cancer, pancreatic cancer, hepatocellular cancer, gallbladder carcinomas, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large cell lymphoma, multiple myeloma, Ewing's sarcoma, chondrosarcomas, osteosarcomas, renal cell carcinoma, bladder carcinoma, testicular carcinoma, seminoma, nonseminoma, squamous cell carcinoma of the head and neck, salivary gland tumors, Sjogren syndrome, mixed connective tissue disease, Whipple disease, Paget's disease of bone, osteomalaci, decreased immune function and decreased muscle mass.
20 . A method of treating a disease associated with senescence in a human subject, comprising:
administering to the subject a therapeutically effective amount of an agent that decreases the subject's blood level of FSH and that decreases the subject's blood level of LH to at or near 0.4 mIU/mL in order to treat a disease associated with senescence,
the subject being a female over the age of 35 years old,
the agent comprising one or more of GnRH, leuprolide, triptorelin, buserelin, nafarelin, desorelin, histrelin, or goserelin, or a physiologically acceptable analog, metabolite, precursor or salt thereof,
the disease selected from the group consisting of: polyps of the colon, colorectal cancer, myeloproliferative diseases, Hodgkin's disease, multiple myeloma, transient myeloproliferative disorder (TMD; also known as transient myeloproliferative syndrome), congenital transient leukemia, congenital leukemoid reaction, transient leukaemoid proliferation, transient abnormal myelopoiesis, acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL; also known as erythro-megakaryoblastic leukaemia), polycythemia, thrombocythemia, myelodysplastic syndromes, myelofibrosis, hypereosinophilic syndrome (HES), hairy-cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, prolymphocytic leukemia, common B lineage acute lymphoblastic leukemia, other leukemias, other myelogenous cancers, osteoarthritis, cataracts, macular degeneration, hearing loss, stroke, peripheral neuropathy, COPD, hypertension, type 2 diabetes, sarcopenia, hypertension, primary pulmonary hypertension, congestive heart failure, left ventricular hypertrophy, cardiac valvular disease, esophagitis, esophageal stricture, gastroparesis, chronic pancreatitis, hypercholesterolemia, hypertriglyceridemia, cirrhosis of the liver, hepatitis, cholelithiasis, cholecystitis, ulcerative colitis, inflammatory bowel disease, Crohn's disease, fibromyalgia, obesity, renal failure, proteinuria, gout, hyperuricemia, membranous nephropathy, polyarteritis nodosa, polymyalgia rheumatica, rheumatoid arthritis, progressive systemic sclerosis, migraine headaches, male pattern baldness, sarcoidosis, Wegener granulomatosis, amyloidosis, dermatomyositis, graft versus host disease, systemic lupus erythematosus, seborrheic dermatitis, psoriasiform eczematous dermatitis, papulosquamous eczematous dermatitis, psoriasis, seborrheic keratosis, anagen effluvium, dysphagia, Barrett esophagus, achalasia, Chagas disease, myasthenia gravis, multiple sclerosis, transverse myelitis, Parkinson's disease, squamous cell carcinoma of the lung, adenocarcinoma of the lung, large cell carcinoma of the lung, small cell carcinoma of the lung, esophageal cancer, gastric cancer, pancreatic cancer, hepatocellular cancer, gallbladder carcinomas, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large cell lymphoma, multiple myeloma, Ewing's sarcoma, chondrosarcomas, osteosarcomas, renal cell carcinoma, bladder carcinoma, squamous cell carcinoma of the head and neck, salivary gland tumors, Sjogren syndrome, mixed connective tissue disease, Whipple disease, Paget's disease of bone, osteomalaci, decreased immune function and decreased muscle mass.